Who owns Dyne Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of DYN from SEC Form 13F filings across 269 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 269 institutions disclosed 213.6M shares of Dyne Therapeutics, Inc. worth $3.45B — about 129.1% of shares outstanding; the largest disclosed holder is T. Rowe Price Investment Management, Inc.. Source: SEC Form 13F filings, parsed by EvidInvest.
269
13F holders
$3.45B
value, 2026 filers
129.1%
of shares outstanding (213.6M sh)
62
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of DYN's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | T. Rowe Price Investment Management, Inc. | 34.3M | $552.1M | 0.4% | 20.7% | +10.9% |
| 2 | BlackRock, Inc. | 14.5M | $233.1M | 0.0% | 8.7% | +16.7% |
| 3 | Janus Henderson Group Ltd.NEW | 12.0M | $193.9M | 0.1% | 7.3% | new |
| 4 | FMR LLC | 11.1M | $179.6M | 0.0% | 6.7% | -0.5% |
| 5 | WELLINGTON MANAGEMENT GROUP LLP | 10.6M | $170.4M | 0.0% | 6.4% | +20080.3% |
| 6 | STATE STREET CORP | 8.2M | $131.4M | 0.0% | 4.9% | +9.4% |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 7.6M | $121.7M | 0.0% | 4.6% | +19.7% |
| 8 | Orbis Allan Gray Ltd | 7.3M | $118.1M | 0.4% | 4.4% | +4.7% |
| 9 | Vestal Point Capital, LP | 6.2M | $99.9M | 2.6% | 3.7% | +83.7% |
| 10 | VANGUARD PORTFOLIO MANAGEMENT LLC | 4.7M | $75.6M | 0.0% | 2.8% | +15.9% |
| 11 | TCG Crossover Management, LLC | 4.6M | $74.3M | 2.1% | 2.8% | 0.0% |
| 12 | GEODE CAPITAL MANAGEMENT, LLC | 4.4M | $70.8M | 0.0% | 2.7% | +17.4% |
| 13 | Frazier Life Sciences Management, L.P. | 3.9M | $62.1M | 1.5% | 2.3% | +22.2% |
| 14 | PRICE T ROWE ASSOCIATES INC /MD/ | 3.7M | $60.0M | 0.0% | 2.3% | -5.4% |
| 15 | FCPM III SERVICES B.V. | 3.6M | $57.8M | 5.4% | 2.2% | -6.8% |
| 16 | Atlas Venture Life Science Advisors, LLC | 3.4M | $55.4M | 8.8% | 2.1% | -49.4% |
| 17 | MPM BIOIMPACT LLC | 3.2M | $51.7M | 3.8% | 1.9% | +66.9% |
| 18 | Logos Global Management LP | 3.0M | $48.3M | 2.6% | 1.8% | +17.6% |
| 19 | JPMORGAN CHASE & CO | 2.9M | $47.4M | 0.0% | 1.8% | -7.6% |
| 20 | ARMISTICE CAPITAL, LLC | 2.7M | $43.1M | 0.5% | 1.6% | -13.3% |
| 21 | BANK OF AMERICA CORP /DE/ | 2.6M | $41.2M | 0.0% | 1.5% | +14.4% |
| 22 | Sofinnova Investments, Inc. | 2.5M | $40.5M | 1.8% | 1.5% | +51.4% |
| 23 | Siren, L.L.C. | 2.4M | $39.1M | 0.9% | 1.5% | +14.1% |
| 24 | Polar Capital Holdings Plc | 2.3M | $36.6M | 0.1% | 1.4% | +76.5% |
| 25 | Venrock Adviser, LLC | 2.2M | $35.0M | 1.7% | 1.3% | 0.0% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.